<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481104</url>
  </required_header>
  <id_info>
    <org_study_id>NS2330-004</org_study_id>
    <nct_id>NCT00481104</nct_id>
  </id_info>
  <brief_title>Evaluation of Long Term Safety of Tesofensine in Patients With Obesity</brief_title>
  <official_title>Evaluation of Long Term Safety of Tesofensine in Patients With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroSearch A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroSearch A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to evaluate the long term safety of tesofensine in obese patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measures: Treatment emergent adverse events, vital signs (BP and HR), ophthalmoscopy, ECG, laboratory assessments and physical examination</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect measures: Body weight, waist circumference, waist-hip ratio, BMI, Metabolic measures</measure>
  </secondary_outcome>
  <enrollment type="Actual">140</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tesofensine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who have completed their participation in TIPO-1&#xD;
&#xD;
          -  Males and females 18 to 65,5 years of age, extremes included&#xD;
&#xD;
          -  Patients continuously receiving diet therapy as well as instructions on exercise&#xD;
&#xD;
          -  Females of childbearing potential must be non-pregnant and use safe contraceptive&#xD;
             methods (the pill, IUD, injection of prolonged gestagen, sub dermal implantation,&#xD;
             hormonal vaginal devices, transdermal patches or surgically sterilized)&#xD;
&#xD;
          -  Patients should be able to comply with study procedures&#xD;
&#xD;
          -  Patients giving written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a BMI&lt; 22&#xD;
&#xD;
          -  Use of prescription medication as listed in Appendix 1&#xD;
&#xD;
          -  Positive pregnancy test for women of childbearing potential&#xD;
&#xD;
          -  Pregnant women, or women who are planning to become pregnant within the next 8 months&#xD;
&#xD;
          -  Patients with specific diseases interfering with their metabolism e.g. untreated&#xD;
             myxoedema, Cushing's syndrome, Type 1 diabetes mellitus, significant neurological or&#xD;
             psychiatric illness such as epilepsy, schizophrenia, depression, eating disorders such&#xD;
             as bulimia.&#xD;
&#xD;
          -  Patients with Type 2 diabetes mellitus are ineligible unless anti-diabetic medication&#xD;
             was not deemed necessary by the investigator and fasting (venous or arterialized&#xD;
             capillary full blood from finger or ear) blood glucose &gt; 6.1 mmol/l at screening.&#xD;
             Re-test is allowed if first measure is above inclusion value. The corresponding&#xD;
             exclusion criteria for plasma glucose is 7.0 mmol/l&#xD;
&#xD;
          -  Patients known to abuse or to be dependent on any drug, including alcohol (weekly&#xD;
             consumption &gt; 21 units of alcohol (men) or &gt;14 units of alcohol (women))&#xD;
&#xD;
          -  Hepatic or renal dysfunction (ASAT and/or ALAT &gt; 2 x ULN and creatinine clearance &lt; 30&#xD;
             mL/min estimated by central laboratory using Cockcroft and Gault formula,&#xD;
             respectively)&#xD;
&#xD;
          -  Known untreated hypercholesterolaemia (&gt; 7 mmol/l). Patients with well regulated&#xD;
             cholesterol using drugs for hypercholesterolaemia are allowed inclusion&#xD;
&#xD;
          -  Known untreated hypertriglyceridaemia (&gt; 3 mmol/l). Patients with well regulated&#xD;
             triglyceride levels using drugs for hypertriglyceridaemia are allowed inclusion&#xD;
&#xD;
          -  Drug treated thyroid diseases (well substituted hypothyroidism is allowed)&#xD;
&#xD;
          -  Patients who suffer from hyperthyroid disease are not allowed in the study, even&#xD;
             though they may be well treated by drugs&#xD;
&#xD;
          -  Patients, who have recently diagnosed, not yet stable hypothyroid disease are not&#xD;
             allowed in the study&#xD;
&#xD;
          -  Patients who suffer from longstanding stable hypothyroid disease, well treated&#xD;
             substitution are allowed to be included including hypothyroidism as a sequelae to&#xD;
             definitive treatment of hyperthyroidism by surgery or radioactive iodine&#xD;
&#xD;
          -  Malabsorptive intestinal disorders that can be assumed to affect the absorption of&#xD;
             tesofensine&#xD;
&#xD;
          -  Special diets (e.g., vegetarian, Atkins)&#xD;
&#xD;
          -  Patients planning major changes in physical activity during the study to an extent&#xD;
             that may interfere with the study outcome, as judged by the investigator&#xD;
&#xD;
          -  Mental or psychiatric disorder based on medical history only&#xD;
&#xD;
          -  Surgically treated obesity&#xD;
&#xD;
          -  Patients with systemic infections or inflammatory diseases&#xD;
&#xD;
          -  History or presence of significant cardiovascular disease such as heart failure,&#xD;
             ischemic heart disease, stroke, transient ischemic attacks&#xD;
&#xD;
          -  Significant abnormalities on the ECG. according to the investigators opinion.&#xD;
             Additional exclusionary ECG values: QTcB &gt; 480 milliseconds (ms) in females and &gt;450&#xD;
             ms in males, PR interval &gt; 240 ms, QRS interval &gt; 120 ms&#xD;
&#xD;
          -  Hypotension (i.e. supine systolic BP &lt; 90 mm Hg) and/or symptomatic orthostatic&#xD;
             hypotension (clinical symptoms of orthostatic hypotension associated with a decline ≥&#xD;
             20 mm Hg in systolic BP at one minute after standing compared with the previous supine&#xD;
             systolic BP obtained after 5 minutes of quiet rest) at screening visit&#xD;
&#xD;
          -  Uncontrolled hypertension (i.e. sitting diastolic BP ≥ 95 mm Hg and sitting systolic&#xD;
             BP ≥ 155 mm Hg) despite treatment for &gt; 4 weeks prior to the screening visit as well&#xD;
             as HR&gt;90 bpm&#xD;
&#xD;
          -  Known HIV infection (no tests required)&#xD;
&#xD;
          -  History of cancer within the past 5 years, excluding treated basal cell carcinoma&#xD;
&#xD;
          -  Clinically significant or potentially disabling eye disorder, including uncontrolled&#xD;
             glaucoma&#xD;
&#xD;
          -  Current treatment with medication with known ocular toxicity such as chloroquine and&#xD;
             hydroxychloroquine is prohibited&#xD;
&#xD;
          -  Patients treated with an investigational drug within 30 days or 5 half-lives&#xD;
             (whichever is longer) preceding the first dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arne V Astrup, Professor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Life Science, University of Copenhagen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Life Sciences, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <state>Frederiksberg</state>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>May 31, 2007</study_first_submitted>
  <study_first_submitted_qc>May 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2007</study_first_posted>
  <last_update_submitted>July 1, 2011</last_update_submitted>
  <last_update_submitted_qc>July 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2011</last_update_posted>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

